By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Asterias Biotherapeutics 

6300 Dumbarton Circle

Fremont  California  94555  U.S.A.
Phone: 510-456-3800 Fax: n/a



Company News
AIVITA Comments On Positive Findings From Asterias Biotherapeutics' SCiStar Trial For Spinal Cord Injury 6/14/2017 8:11:59 AM
Patients With Complete Paralysis Show Additional Recovery Of Arm, Hand And Finger Function At 9-Months After Treatment With Asterias Biotherapeutics' AST-OPC1 6/13/2017 7:28:06 AM
Bay Area's Asterias Biotherapeutics CEO to Step Down, New Leader Named 5/24/2017 10:35:55 AM
Asterias Biotherapeutics Reports First Quarter Financial Results And Recent Development Progress 5/12/2017 8:19:28 AM
New MRI Data From Asterias Biotherapeutics' Ongoing SCiStar Clinical Study Indicates AST-OPC1 Cells Prevent Formation Of Damaging Lesion Cavities In Patients Suffering Severe Spinal Cord Injury 5/11/2017 7:34:23 AM
Asterias Biotherapeutics To Report First Quarter Results On May 11, 2017 5/4/2017 9:45:34 AM
Asterias Biotherapeutics Announces Publication Of Positive Phase II Data On AST-VAC1 For The Treatment Of Acute Myeloid Leukemia (AML) In 'Cancer' 4/26/2017 6:27:13 AM
Asterias Biotherapeutics Announces Data Monitoring Committee Unanimously Recommends Continuation Of Scistar Phase I/IIa Clinical Trial Of AST-OPC1 For Cervical Spinal Cord Injury 4/25/2017 6:56:35 AM
Asterias Biotherapeutics Reports Fourth Quarter And Full Year 2016 Financial Results And Highlights Recent Development Progress 3/29/2017 8:30:53 AM
Asterias Biotherapeutics Release: Update On Full Six-Patient Cohort Confirms Patients With Complete Paralysis Can Experience Meaningful Recovery Of Function By Six Months Following AST-OPC1 Treatment 3/21/2017 6:41:51 AM